Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gloom Is Overblown: Allergy Vaccine Sector Is Poised To Globalize

Executive Summary

The failure of Circassia’s cat allergy vaccine product in a Phase III study, and other recent setbacks including a one-year delay to Allergy Therapeutics’ US ambitions, have not stymied the excitement in a sector that promises new approaches to grass, tree, peanut and other food allergies, and much more convenient treatment regimens.


Related Content

Turmoil In Allergy Market Continues As Merck Ends ALK Partnership
Circassia's Harris Deeply Frustrated By Phase III Cat Allergy Flop
Merck & Co Extending Allergy Interests With House Dust Mite Filing


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts